Advanced search×

Management of behavioral problems in Alzheimer's disease.

Int Psychogeriatr 22(3):346-72 (2010) PMID 20096151

Alzheimer's disease (AD) is a complex progressive brain degenerative disorder that has effects on multiple cerebral systems. In addition to cognitive and functional decline, diverse behavioral changes manifest with increasing severity over time, presenting significant management challenges for caregivers and health care professionals. Almost all patients with AD are affected by neuropsychiatric symptoms at some point during their illness; in some cases, symptoms occur prior to diagnosis of the dementia syndrome. Further, behavioral factors have been identified, which may have their origins in particular neurobiological processes, and respond to particular management strategies. Improved clarification of causes, triggers, and presentation of neuropsychiatric symptoms will guide both research and clinical decision-making. Measurement of neuropsychiatric symptoms in AD is most commonly by means of the Neuropsychiatric Inventory; its utility and future development are discussed, as are the limitations and difficulties encountered when quantifying behavioral responses in clinical trials. Evidence from clinical trials of both non-pharmacological and pharmacological treatments, and from neurobiological studies, provides a range of management options that can be tailored to individual needs. We suggest that non-pharmacological interventions (including psychosocial/psychological counseling, interpersonal management and environmental management) should be attempted first, followed by the least harmful medication for the shortest time possible. Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class.

DOI: 10.1017/S1041610209991505
Version: za2963e q8za3 q8zba q8zc5 q8zd5 q8ze3 q8zf4 q8zg1

Similar articles you may find interesting…

  1. Management of eustachian tube dysfunction with nasal steroid spray: a prospective, randomized, placebo-controlled trial.

    Arch Otolaryngol Head Neck Surg 137(5):449-55 (2011) PMID 21576556

    To determine the efficacy of intranasal aqueous triamcinolone acetonide in treating the tympanometric signs and symptoms of eustachian tube dysfunction, such as otitis media with effusion and negative middle ear pressure. Randomized, placebo-controlled, double-blind p...
  2. Labral support shelf arthroplasty for the early stages of severe Legg-Calvé-Perthes disease.

    Am J Orthop (Belle Mead NJ) 39(1):26-9 (2010) PMID 20305837

    The best treatment for Legg-Calvé-Perthes disease remains unknown, and various methods of treatment have been shown to yield conflicting results. Treatment with a labral support shelf arthroplasty is ideal when an increased arc of the acetabulum is needed to contain an enlarged femoral head, when e...
  3. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers

    Clin Pharmacol Ther 72(3):11 (2002) PMID 12235452

    Enoxaparin was well tolerated when administered subcutaneously or intravenously, and there appears to be no need to modify the currently recommended dose for obese volunteers....